NYU Cancer Health Disparity (CHD) SPORE

项目总结 口腔消化道(ODT)癌症占美国癌症死亡人数的32%，具有明显的种族差异 发病率和死亡负担的差异。我们的中心假设是，人类微生物群对 通过微生物群与宿主在ODT致癌过程中的生物相互作用来实现ODT癌的差异。这个 纽约大学癌症健康差异(CHD)孢子的总体目标是开发一个全面的翻译 确定、理解和控制口部消化轨迹(ODT)微生物区系的研究计划 癌症差异。项目1将侧重于口腔微生物群与种族和社会经济的关系。 头颈部癌发病率的差异，通过嵌套的前瞻性病例对照研究 3个高度多样化的大型美国队列。项目2将重点放在肠道微生物群和黑人和白人种族 接受辅助化疗的结肠癌患者肿瘤复发的差异。我们的研究将 通过以下共享核心得到大力支持：(A)行政、(B)生物制品采购和利用，以及 (C)生物统计学和生物信息学。该提案汇集了一支高度跨学科的调查团队 在拟议研究的每个阶段进行协作，以实现以下翻译目标 这个P20应用程序。纽约大学CHD孢子将提供关于特定人类微生物区系的新知识， 有助于ODT癌症的差异，并将促进我们对这些疾病的功能后果的理解 微生物区系在ODT致癌中的作用从P20孢子中拟议的研究中获得的知识将 通过确定少数民族人群中的ODT癌症高危人群来改变当前的临床实践，这将 为开发基于微生物的个性化预防、临床决策工具和 解决ODT癌差异的预防性干预措施。P20孢子的取得将为今后的发展打下坚实的基础 为P50孢子翻译这些微生物因素的循证发现奠定了基础 将ODT癌症差异转化为临床和社区层面可操作的基于实践的干预措施。

PROJECT SUMMARY Orodigestive tract (ODT) cancers, which account for 32% of cancer deaths in the US, exhibit striking racial disparities in incidence and mortality burdens. Our central hypothesis is that the human microbiome contributes to ODT cancer disparities through biologic interaction of the microbiome with the host in ODT oncogenesis. The overall objective of the NYU Cancer Health Disparity (CHD) SPORE is to develop a comprehensive translational research program to identify, understand and control the microbiota that account for orodigestive track (ODT) cancer disparities. Project 1 will focus on the relationship of the oral microbiome to racial and socioeconomic disparities in the incidence of head and neck cancer, by means of a prospective case-control study nested within 3 large highly diverse US cohorts. Project 2 will focus on the gut microbiome and Black and White racial disparities in tumor recurrence in colon cancer patients who received adjuvant chemotherapy. Our research will be strongly supported through shared Cores: (A) Administrative, (B) Biospecimen Procurement & Utilization, and (C) Biostatistics and Bioinformatics. The proposal brings together a highly transdisciplinary team of investigators that work collaboratively through every stage of the proposed research to accomplish the translational goal of this P20 application. The NYU CHD SPORE will provide new knowledge on specific human microbiota that contribute to ODT cancer disparities and will advance our understanding of the functional consequences of these microbiota in ODT oncogenesis. The knowledge gained from the proposed research in the P20 SPORE will transform current clinical practice by identifying high risk groups for ODT cancer in minority populations, that will provide the scientific basis for developing microbially-based personalized prevention, clinical decision tools, and prophylactic interventions to address ODT cancer disparities. Achievement of the P20 SPORE will lay a solid groundwork for a P50 SPORE to translate these evidence-based findings of microbial factors contributing to ODT cancer disparity into actionable practice-based interventions at the clinic and community level.